Cargando…

Circulating selenoprotein P levels predict glucose‐lowering and insulinotropic effects of metformin, but not alogliptin: A post‐hoc analysis

AIMS/INTRODUCTION: Selenoprotein P (SeP; encoded by SEPP1 in humans) is a hepatokine that causes impaired insulin secretion and insulin resistance. Metformin downregulates SELENOP promoter activity through an adenosine monophosphate‐activated kinase–forkhead box protein O3a pathway in hepatocytes. T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takeshita, Yumie, Tanaka, Takeo, Takayama, Hiroaki, Kita, Yuki, Goto, Hisanori, Nakano, Yujiro, Saito, Yoshiro, Takamura, Toshinari
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9889665/ https://www.ncbi.nlm.nih.gov/pubmed/36479595 http://dx.doi.org/10.1111/jdi.13949

Ejemplares similares

Effects of metformin and alogliptin on body composition in people with type 2 diabetes
por: Takeshita, Yumie, et al.
Publicado: (2018)

Insulin–glucagon‐like peptide‐1 receptor agonist relay and glucagon‐like peptide‐1 receptor agonist first regimens in individuals with type 2 diabetes: A randomized, open‐label trial study
por: Takeshita, Yumie, et al.
Publicado: (2022)

Effects of eicosapentaenoic acid on serum levels of selenoprotein P and organ‐specific insulin sensitivity in humans with dyslipidemia and type 2 diabetes
por: Takeshita, Yumie, et al.
Publicado: (2021)

Serum selenoprotein P, but not selenium, predicts future hyperglycemia in a general Japanese population
por: Oo, Swe Mar, et al.
Publicado: (2018)

Inverse Correlation between Serum Levels of Selenoprotein P and Adiponectin in Patients with Type 2 Diabetes
por: Misu, Hirofumi, et al.
Publicado: (2012)

Alcohol Intake Is Associated With Elevated Serum Levels of Selenium and Selenoprotein P in Humans
por: Isobe, Yuki, et al.
Publicado: (2021)

Corrigendum: Alcohol Intake Is Associated With Elevated Serum Levels of Selenium and Selenoprotein P in Humans
por: Isobe, Yuki, et al.
Publicado: (2021)

Metabolic and sympathovagal effects of bolus insulin glulisine versus basal insulin glargine therapy in people with type 2 diabetes: A randomized controlled study
por: Takeshita, Yumie, et al.
Publicado: (2020)

Comparison of Tofogliflozin and Glimepiride Effects on Nonalcoholic Fatty Liver Disease in Participants With Type 2 Diabetes: A Randomized, 48-Week, Open-Label, Active-Controlled Trial
por: Takeshita, Yumie, et al.
Publicado: (2022)

Nutrigenetic Interaction Between Apolipoprotein C3 Polymorphism and Fat Intake in People with Nonalcoholic Fatty Liver Disease
por: Yamamoto, Reina, et al.
Publicado: (2023)

Fat‐free mass and calf circumference as body composition indices to determine non‐exercise activity thermogenesis in patients with diabetes
por: Isobe, Yuki, et al.
Publicado: (2015)

Hepatokine Selenoprotein P-Mediated Reductive Stress Causes Resistance to Intracellular Signal Transduction
por: Takamura, Toshinari
Publicado: (2020)

Sitagliptin versus mitiglinide switched from mealtime dosing of a rapid-acting insulin analog in patients with type 2 diabetes: a randomized, parallel-group study
por: Takeshita, Yumie, et al.
Publicado: (2015)

Somatostatin Receptor-negative and Fluorodeoxyglucose-positron Emission Tomography-positive Lung Neuroendocrine Tumor G1 Exhibiting Cyclic Cushing's Syndrome
por: Nomura, Chiaki, et al.
Publicado: (2022)

Weight-adjusted lean body mass and calf circumference are protective against obesity-associated insulin resistance and metabolic abnormalities
por: Takamura, Toshinari, et al.
Publicado: (2017)

Corrigendum to ‘Weight-adjusted lean body mass and calf circumference are protective against obesity-associated insulin resistance and metabolic abnormalities’
por: Takamura, Toshinari, et al.
Publicado: (2017)

PAC1 Deficiency Protects Obese Male Mice From Immobilization-Induced Muscle Atrophy by Suppressing FoxO–Atrogene Axis
por: Li, Qifang, et al.
Publicado: (2023)

Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus
por: Holland, Daniel Q, et al.
Publicado: (2014)

Selenoprotein P-neutralizing antibodies improve insulin secretion and glucose sensitivity in type 2 diabetes mouse models
por: Mita, Yuichiro, et al.
Publicado: (2017)

Bending of a vertical cannula without alarm during insulin pump therapy as a cause of unexpected hyperglycemia: A Japanese issue?
por: Kuroda, Kaori, et al.
Publicado: (2015)

Metformin Prevents and Reverses Inflammation in a Non-Diabetic Mouse Model of Nonalcoholic Steatohepatitis
por: Kita, Yuki, et al.
Publicado: (2012)

Vildagliptin vs liraglutide as a second-line therapy switched from sitagliptin-based regimens in patients with type 2 diabetes: A randomized, parallel-group study
por: Takeshita, Yumie, et al.
Publicado: (2015)

Study Protocol for Pleiotropic Effects and Safety of Sodium–Glucose Cotransporter 2 Inhibitor Versus Sulfonylurea in Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
por: Takeshita, Yumie, et al.
Publicado: (2020)

Selenoprotein P as an in vivo redox regulator: disorders related to its deficiency and excess
por: Saito, Yoshiro
Publicado: (2020)

Selenium Transport Mechanism via Selenoprotein P—Its Physiological Role and Related Diseases
por: Saito, Yoshiro
Publicado: (2021)

Mealtime dosing of a rapid-acting insulin analog reduces glucose variability and suppresses daytime cardiac sympathetic activity: a randomized controlled study in hospitalized patients with type 2 diabetes
por: Kanamori, Takehiro, et al.
Publicado: (2018)

Renoprotective effects of atorvastatin compared with pravastatin on progression of early diabetic nephropathy
por: Takazakura, Akiko, et al.
Publicado: (2015)

The effect of alogliptin on pulmonary function in obese patients with type 2 diabetes inadequately controlled by metformin monotherapy
por: Tai, He, et al.
Publicado: (2016)

Liver steatosis is associated with insulin resistance in skeletal muscle rather than in the liver in Japanese patients with non-alcoholic fatty liver disease
por: Kato, Ken-ichiro, et al.
Publicado: (2015)

The Cost-Effectiveness of Alogliptin Versus Sulfonylurea as Add-on Therapy to Metformin in Patients with Uncontrolled Type 2 Diabetes Mellitus
por: Gordon, Jason, et al.
Publicado: (2016)

The effect of alogliptin on pulmonary function in obese patients with type 2 diabetes inadequately controlled by metformin monotherapy: Erratum
Publicado: (2016)

Endogenous Selenoprotein P, a Liver-Derived Secretory Protein, Mediates Myocardial Ischemia/Reperfusion Injury in Mice
por: Chadani, Hiroshi, et al.
Publicado: (2018)

LECT2 as a hepatokine links liver steatosis to inflammation via activating tissue macrophages in NASH
por: Takata, Noboru, et al.
Publicado: (2021)

A novel PHEX mutation associated with vitamin D-resistant rickets
por: Sako, Saori, et al.
Publicado: (2019)

Impacts of Glucose-Dependent Insulinotropic Polypeptide on Orthodontic Tooth Movement-Induced Bone Remodeling
por: Yamauchi, Taisuke, et al.
Publicado: (2022)

Alogliptin-Induced Minimal Change Nephrotic Syndrome and Interstitial Nephritis
por: Shima, Hisato, et al.
Publicado: (2019)

Testing the Therapeutic Equivalence of Alogliptin, Linagliptin, Saxagliptin, Sitagliptin or Vildagliptin as Monotherapy or in Combination with Metformin in Patients with Type 2 Diabetes
por: Messori, Andrea, et al.
Publicado: (2014)

Anti‐inflammatory role of glucose‐dependent insulinotropic polypeptide in periodontitis
por: Suzuki, Yuki, et al.
Publicado: (2016)

Pleiotropic effects of sitagliptin versus voglibose in patients with type 2 diabetes inadequately controlled via diet and/or a single oral antihyperglycemic agent: a multicenter, randomized trial
por: Matsushima, Yukiko, et al.
Publicado: (2016)

Alogliptin benzoate for management of type 2 diabetes
por: Saisho, Yoshifumi
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_3bjhqr8fpqunib32s2kl3b9a0i